Molina Healthcare (MOH) Stock Forecast & Price Target

Molina Healthcare is a high-quality pure-play government-sponsored managed care franchise whose earnings power is anchored by more than 5 million members, over 85% of whom are Medicaid beneficiaries, with concentrated but durable scale in California, New York, Texas, and Washington that supports strong visibility into premium revenue and contract retention. The positive outlook rests on a compelling recovery bridge: the company is positioned to benefit from structural underfunding in managed Medicaid, where rates currently trail trend by about 100 bps and industry underfunding is roughly 300 bps, and each 100 bps of Medicaid MCR improvement is worth approximately $5.00 in EPS, while management also has upside from a conservative 33% new RFP win assumption, a potential 100–150 bps of AI-driven margin improvement, and long-term Duals expansion from 6% toward a market-share profile more in line with its 16% Medicaid footprint. Nearer term, the thesis is reinforced by known earnings catalysts including the Florida CMS contract adding about $6B of annual run-rate revenue and roughly $2.00/share at full implementation, the MAPD exit removing about $1.00/share of drag, and operating leverage on about $6B of new revenue, making the stock attractive because the core business has already demonstrated industry-leading Medicaid margins and a management team that has repeatedly scaled premium revenue through disciplined execution.

Molina Healthcare is viewed negatively because its core earnings framework has proven fragile, with embedded earnings revised from more than $11 per share to $9.00 per share at the May 2026 Investor Day after the Florida CMS contribution was reset from $4.50 to about $2.00 per share, underscoring that even the company’s best growth assumptions are highly execution-sensitive. Its investment case is also exposed to concentrated contract and policy risk, since more than 85% of members come from Medicaid, over half of enrollees are tied to California, New York, Texas, and Washington, and the Florida CMS contract alone adds roughly $6 billion in annual run-rate premium, about 15% of total revenue, while carrying start-up and margin uncertainty even as management targets mid-to-low single digit pretax margins pre-inception. On top of that, the company faces structural pressure from Medicaid cost trends that were 7.5% in 2025, a 2026 environment of flat or weaker government rate adequacy, and marketplace and Medicare volatility, leaving the path to margin recovery dependent on timing, contract execution, and favorable regulatory outcomes rather than a clean fundamental inflection.